Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D007172:Erectile Dysfunction / Q000139:chemically induced*; D005485:Flutamide / Q000009:adverse effects / Q000627:therapeutic use*; D017273:Goserelin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007422:Intestines / Q000528:radiation effects; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000528:radiation effects
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D005485:Flutamide